Jeff Yass’s La Jolla Pharmaceutical Company LJPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-14,800
| Closed | -$47K | – | 14930 |
|
|
2022
Q2 | $47K | Sell |
14,800
-7,800
| -35% | -$30.4K | ﹤0.01% | 12020 |
|
|
2022
Q1 | $97K | Buy |
22,600
+2,500
| +12% | +$10.9K | ﹤0.01% | 11940 |
|
|
2021
Q4 | $93K | Buy |
20,100
+8,700
| +76% | +$36.3K | ﹤0.01% | 12198 |
|
|
2021
Q3 | $45K | Buy |
+11,400
| New | +$45.2K | ﹤0.01% | 12382 |
|
|
2021
Q2 | – | Sell |
-12,100
| Closed | -$51K | – | 13786 |
|
|
2021
Q1 | $51K | Sell |
12,100
-7,300
| -38% | -$40.2K | ﹤0.01% | 12031 |
|
|
2020
Q4 | $75K | Sell |
19,400
-20,800
| -52% | -$88.9K | ﹤0.01% | 10622 |
|
|
2020
Q3 | $162K | Buy |
40,200
+27,800
| +224% | +$115K | ﹤0.01% | 9630 |
|
|
2020
Q2 | $53K | Sell |
12,400
-10,300
| -45% | -$62.7K | ﹤0.01% | 9736 |
|
|
2020
Q1 | $95K | Buy |
22,700
+1,800
| +9% | +$11.4K | ﹤0.01% | 9361 |
|
|
2019
Q4 | $82K | Sell |
20,900
-44,600
| -68% | -$263K | ﹤0.01% | 9211 |
|
|
2019
Q3 | $576K | Sell |
65,500
-78,400
| -54% | -$741K | ﹤0.01% | 6976 |
|
|
2019
Q2 | $1.33M | Buy |
143,900
+133,000
| +1,220% | +$1M | ﹤0.01% | 5040 |
|
|
2019
Q1 | $70K | Sell |
10,900
-5,100
| -32% | -$33.2K | ﹤0.01% | 8390 |
|
|
2018
Q4 | $151K | Sell |
16,000
-112,200
| -88% | -$1.69M | ﹤0.01% | 7979 |
|
|
2018
Q3 | $2.58M | Buy |
128,200
+100,800
| +368% | +$2.63M | ﹤0.01% | 3598 |
|
|
2018
Q2 | $799K | Sell |
27,400
-30,800
| -53% | -$951K | ﹤0.01% | 5824 |
|
|
2018
Q1 | $1.73M | Buy |
58,200
+20,100
| +53% | +$648K | ﹤0.01% | 4193 |
|
|
2017
Q4 | $1.23M | Sell |
38,100
-15,900
| -29% | -$520K | ﹤0.01% | 4839 |
|
|
2017
Q3 | $1.88M | Sell |
54,000
-59,800
| -53% | -$1.92M | ﹤0.01% | 4036 |
|
|
2017
Q2 | $3.39M | Buy |
113,800
+58,200
| +105% | +$1.67M | ﹤0.01% | 2962 |
|
|
2017
Q1 | $1.66M | Buy |
55,600
+3,800
| +7% | +$97K | ﹤0.01% | 4068 |
|
|
2016
Q4 | $908K | Sell |
51,800
-12,200
| -19% | -$234K | ﹤0.01% | 5738 |
|
|
2016
Q3 | $1.52M | Buy |
64,000
+14,700
| +30% | +$277K | ﹤0.01% | 4010 |
|
|
2016
Q2 | $789K | Sell |
49,300
-9,200
| -16% | -$165K | ﹤0.01% | 5328 |
|
|
2016
Q1 | $1.22M | Buy |
58,500
+23,300
| +66% | +$416K | ﹤0.01% | 4689 |
|
|
2015
Q4 | $950K | Sell |
35,200
-26,700
| -43% | -$728K | ﹤0.01% | 5513 |
|
|
2015
Q3 | $1.72M | Sell |
61,900
-20,300
| -25% | -$640K | ﹤0.01% | 4567 |
|
|
2015
Q2 | $2.02M | Buy |
+82,200
| New | +$1.69M | ﹤0.01% | 4707 |
|
Jeff Yass's LJPC Position: Q3 2022 in Review
Jeff Yass sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 22,193 shares — an estimated $71K sold.
Jeff Yass first reported a position in LJPC in Q1 2015 and held it in 23 quarters. The position peaked at $7.13M in Q3 2017. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.
- Jeff Yass reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
- Jeff Yass sold 22,193 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $71K.
- Jeff Yass first reported a position in La Jolla Pharmaceutical Company in Q1 2015 and held it in 23 quarters.
- Jeff Yass's La Jolla Pharmaceutical Company position peaked at $7.13M in Q3 2017.
- 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.
Based on Susquehanna International Group's 13F filing for Q3 2022, filed 14 Nov 2022.